Physician profile
Dina Dahan
NPI 1093806655
$4,883.40
in general payments reported to CMS, 2019-2025
27 companies · $565 in 2025
The $565 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,147 · 2020: $352 · 2021: $759 · 2022: $319 · 2023: $111 · 2024: $631 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $1,594.85 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $426.18 | 2019-2021 | |
| Ucb, INC. | $400.50 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Eisai INC. | $305.19 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $294.96 | 2021-2024 | Qelbree |
| Greenwich Biosciences, INC. | $269.15 | 2019-2021 | |
| Abbvie INC. | $253.86 | 2023-2025 | Qulipta |
| Jazz Pharmaceuticals INC. | $247.14 | 2019-2025 | |
| Insightec,INC | $170.93 | 2022 | |
| Neurelis, INC. | $138.69 | 2020-2025 | Valtoco |
| Biohaven Pharmaceuticals, INC. | $130.97 | 2021 | |
| Sk Life Science, INC. | $126.58 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $113.46 | 2023-2024 | Aptiom |
| Upsher-Smith Laboratories LLC | $61.44 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $56.78 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $42.61 | 2024 | Rexulti |
| Livanova USA, INC. | $31.00 | 2022 | |
| Aquestive Therapeutics, INC. | $30.60 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $27.74 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $26.49 | 2024 | |
| Mallinckrodt Enterprises LLC | $22.43 | 2019 | |
| Ge Healthcare | $22.19 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $21.53 | 2024 | Austedo Xr |
| Biogen, INC. | $19.69 | 2019 | |
| Zogenix INC. | $17.85 | 2021 | |
| Aucta Pharmaceuticals, INC. | $16.06 | 2025 | Motpoly Xr |
| Amneal Pharmaceuticals LLC | $14.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Dahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.